Research programme: obesity therapy - AdipoGenix/CombinatoRx
Latest Information Update: 14 Aug 2009
At a glance
- Originator AdipoGenix; CombinatoRx
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 14 Aug 2009 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 16 May 2006 Preclinical trials in Obesity in USA (unspecified route)